Ager, Ann ![]() ![]() |
Preview |
PDF
- Accepted Post-Print Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (159kB) | Preview |
Official URL: https://doi.org/10.1016/j.cell.2023.03.005
Abstract
The discovery of immune checkpoint inhibitors that boost T cell activity has revolutionized cancer treatment. However, these therapies do not work in all patients, and the quest is on to understand why. Two new studies published in this issue of Cell reveal the surprising finding that activated T cells can recruit neutrophils to kill cancer cells.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine |
Publisher: | Elsevier |
ISSN: | 0092-8674 |
Date of First Compliant Deposit: | 24 May 2023 |
Date of Acceptance: | 3 March 2023 |
Last Modified: | 11 Nov 2024 12:00 |
URI: | https://orca.cardiff.ac.uk/id/eprint/158515 |
Citation Data
Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |